Avid bioservices announces receipt of deficiency notice from nasdaq regarding late form 10-q

Tustin, calif., march 20, 2024 (globe newswire) -- avid bioservices, inc. (nasdaq:cdmo), a dedicated biologics contract development and manufacturing organization (cdmo), announced today it received a notice (the “notice”) on march 19, 2024 from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) advising the company that it was not in compliance with nasdaq's continued listing requirements under nasdaq listing rule 5250(c)(1) (the “rule”) as a result of its failure to file its quarterly report on form 10-q for the fiscal quarter ended january 31, 2024 (the “form 10-q”) in a timely manner.
CDMO Ratings Summary
CDMO Quant Ranking